Konidaris Tasos 4
4 · Amneal Pharmaceuticals, Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Konidaris Tasos
Executive Vice President & CFO
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-03-02+72,622→ 72,622 total→ Class A Common Stock (72,622 underlying) - Award
Performance-Based Restricted Stock Units
[F3][F4]2026-03-02+72,622→ 72,622 total→ Class A Common Stock (72,622 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]The restricted stock units vest in four equal annual installments beginning on March 2, 2027.
- [F3]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F4]Represents a performance-based restricted stock unit grant of 72,622 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.
Signature
/s/ Denis Butkovic, Attorney-in-Fact|2026-03-03